ライフサイエンスコーパス: leukocyte antigen

1 s without the need for presentation by human leukocyte antigen.

2 expressed antibody that bound all Bw4 human leukocyte antigen-A and human leukocyte antigen-B antige

3 ll patients' results were positive for human leukocyte antigen-A29.

4 nce of C1q-binding donor-specific anti-human leukocyte antigen alloantibody, as determined retrospect

5 tudies have revealed associations with human leukocyte antigen and non-human leukocyte antigen genes

6 tion between HIV genetic variation and human leukocyte antigen and the other studying host range dist

7 ts develop de novo donor-specific anti-human leukocyte antigen antibodies (dnDSA) after transplantati

8 Monitoring anti-human leukocyte antigen antibodies after cellular rejection ma

9 d (SAB) assay measuring C1q binding to human leukocyte antigen antibodies has recently been introduce

10 Serologic determination of human leukocyte antigen antibodies showed higher positivity fo

11 Anti-human leukocyte antigen antibodies were analyzed before and af

12 the 1,974 C1q-negative SABs contained human leukocyte antigen antibodies with strong complement-bind

13 e, human leukocyte antigen mismatches, human leukocyte antigen antibodies, cold ischemia time, living

14 caid Services to evaluate whether anti-human leukocyte antigen antibodies, measured as panel reactive

15 lant recipients have pre-existing anti-human leukocyte antigen antibodies.

16 ay be limited by the formation of anti-human leukocyte antigen antibodies.

17 in transplantation settings to deplete human leukocyte antigen antibody-producing plasma cells to rev

18 th HIV/Mtb had decreased expression of human leukocyte antigen antigen D related and the costimulator

19 e production and significantly reduced human leukocyte antigen - antigen D related expression.

20 onse to bacterial stimulation and less human leukocyte antigen - antigen D related.

21 eripheral blood mononuclear cells, and human leukocyte antigen-antigen D related expression on circul

22 of activated drug-reacting T cells in human leukocyte antigen-associated, drug-induced liver injury.

23 -cell infiltrates and a strong genetic human leukocyte antigen association represent characteristic f

24 all Bw4 human leukocyte antigen-A and human leukocyte antigen-B antigens tested, except B*27:05 and

25 Human leukocyte antigen-B40 group and HLA-B8 were identified a

26 ng the highly sensitive single-antigen human leukocyte antigen bead assay 5.1 +/- 3.9 months after th

27 rategy relies on initial prediction of human leukocyte antigen-binding peptides by in silico algorith

28 owever, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor fro

29 The leukocyte antigen CD69 modulates the setting and progres

30 Human leukocyte antigen class I (HLA)-restricted CD8(+) T lymp

31 years, adjusted P = 0.010) and several human leukocyte antigen class I (HLA-I) alleles, including HLA

32 ient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules.

33 before Nef-mediated downregulation of human leukocyte antigen class I (HLA-I).

34 Purified anti-human leukocyte antigen class I antibody (W6/32), isotype cont

35 ughput 13-parameter flow cytometry and human leukocyte antigen class I cytomegalovirus-specific dextr

36 ng placental trophoblast cells express human leukocyte antigen class I ligands (HLA-E, HLA-G, and HLA

37 lysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular cytok

38 cytometry with ultrasensitive peptide-human leukocyte antigen class I tetramer staining to quantify

39 and c-Met and the immunologic markers human leukocyte antigen class II and programmed death ligand 1

40 ntibodies showed higher positivity for human leukocyte antigen class II donor-specific antibodies in

41 gene, resulting in down-regulation of swine leukocyte antigen class II expression, or from a pig wit

42 ory of type 1 diabetes and susceptible human leukocyte antigen class II genotypes.

43 red by an interaction between gp42 and human leukocyte antigen class II.

44 re, we report the ability of accepting human leukocyte antigen-compatible but ABO-incompatible donors

45 em through their interactions with the human leukocyte antigen complex, and neoantigen presence has r

46 of circulating activated CD4+ T cells (human leukocyte antigen-D related [HLA-DR]+CD38+CD4+) (from 3.

47 monocytes expressed reduced levels of human leukocyte antigen-D-related peptide and released less so

48 Monocyte expression of human leukocyte antigen-D-related peptide, sol-tumor necrosis

49 us therapy or, alternatively, banks of human leukocyte antigen diverse iPSCs are possible for allogen

50 The human leukocyte antigen DQB1*06:02 was absent in all patients.

51 sceptibility genes, HLA-DRbeta1-Arg74 (human leukocyte antigen DR containing an arginine at position

52 hoproliferation and Treg generation in human leukocyte antigen DR matched and mismatched MLRs either

53 n 38 (CD38) and CD69 but low levels of human leukocyte antigen DR, CD80, and CD86 at baseline.

54 evels of macrophage-derived chemokine, human leukocyte antigen DR, CD80, and CD86 were increased in a

55 egulated macrophage-derived chemokine, human leukocyte antigen DR, CD86, and CD80 correlated positive

56 ultured in perioperative serum and CD14Human Leukocyte Antigen-DR (HLA-DR) [monocyte HLA-DR (mHLA-DR)

57 he ocular surface inflammatory markers human leukocyte antigen-DR (HLA-DR) and intercellular adhesion

58 both demonstrated increased levels of human leukocyte antigen-DR (HLA-DR) following IFN-gamma stimul

59 luster of differentiation 163 (CD163), human leukocyte antigen-DR (HLA-DR), and lipopolysaccharide (L

60 nal antibodies against CD14, CD16, and human leukocyte antigen-DR (HLA-DR), and subjected to flow cyt

61 We found a profound decrease in human leukocyte antigen-DR on Mo and DCs in burned patients wi

62 The expression of human leukocyte antigen-DR was determined on all DCs and Mo, a

63 ion of suppressive CD25(high)CD127(low)human leukocyte antigen-DR(+)FoxP3(high) effector regulatory T

64 me B), CD68 (macrophages), and HLA-DR (human leukocyte antigen-DR) antigens (activation marker).

65 lass II (MHC II) and instead expresses human leukocyte antigen DR1 (HLA-DR1).

66 nd an association with the presence of human leukocyte antigen-DR15 were found.

67 zed in SARS-CoV- and MERS-CoV-infected human leukocyte antigen DR2 and DR3 transgenic mice, indicatin

68 class II antigen was replaced with the human leukocyte antigen DR4 (HLA-DR4).

69 Lo Monaco et al. propose that human leukocyte antigen E (HLA-E) and HLA-C expression levels

70 PPCLs uniformly expressed class I human leukocyte antigen, epithelial cell adhesion molecule, an

71 sidedness dependent differential hMSC human leukocyte antigen expression, angiogenic and inflammator

72 tibility complex (MHC) molecule HLA-F (human leukocyte antigen F) regulates the immune system in preg

73 immune tolerance mechanism induced by human leukocyte antigen G (HLA-G), was investigated.

74 mber of the KIR family that recognizes human leukocyte antigen G and mediates NK-cell activation thro

75 uently to this ILT4 up-regulation, the human leukocyte antigen G-mediated inhibition of neutrophil ph

76 Human leukocyte antigen-G (HLA-G) is a nonclassical major hist

77 differentiation preferentially toward human leukocyte antigen-G(+) pcEVT, and that an intact HIF com

78 eptor(+) villous cytotrophoblasts into human leukocyte antigen-G(+) proximal column EVT (pcEVT) and i

79 Invading human leukocyte antigen-G+ (HLA-G+) extravillous trophoblasts

80 kin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA c

81 airwise successfully fine-maps a known human leukocyte antigen gene that is known to cause the diseas

82 r, the functional relationship between human leukocyte antigen gene(s) and disease development remain

83 s with human leukocyte antigen and non-human leukocyte antigen genes of 3 major histocompatibility co

84 he child after adjustment for country, human leukocyte antigen genotype, family history of celiac dis

85 ity and specificity, and by estimating human leukocyte antigen genotypes directly from variant calls.

86 raves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide a

87 Today human leukocyte antigen-haploidentical transplantation is a fe

88 te lymphoblastic leukemia who received human leukocyte antigen-haploidentical transplantation of ex v

89 resent review describes the biology of human leukocyte antigen haplotype mismatched ("haploidentical"

90 The HLA-DRB1*01 allele of the human leukocyte antigen has been associated with acute coronar

91 L (ALY) is presented in the context of human leukocyte antigen HLA-A*02:01 molecules for recognition

92 isk stage III melanoma were grouped by human leukocyte antigen (HLA) -A2 status.

93 ches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow transplanta

94 The expense of human leukocyte antigen (HLA) allele genotyping has motivated

95 ies new associations between classical human leukocyte antigen (HLA) alleles and common immune-mediat

96 searched for genetic associations with human leukocyte antigen (HLA) alleles and IFN-lambda3 gene (IF

97 Despite progress in defining human leukocyte antigen (HLA) alleles for anti-citrullinated-p

98 Specific human leukocyte antigen (HLA) alleles have been identified in

99 e detected the involvement of the same human leukocyte antigen (HLA) alleles in both SCZ and MS, but

100 e-induced immune responses, we imputed human leukocyte antigen (HLA) alleles in patients of European

101 ct of source partner HIV-1 RNA levels, human leukocyte antigen (HLA) alleles, and innate responses th

102 wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and copy-nu

103 disease, is associated with particular human leukocyte antigen (HLA) alleles.

104 We performed human leukocyte antigen (HLA) analysis in 25 nontumor anti-LGI

105 ltiplexed flow cytometry-recorded anti-human leukocyte antigen (HLA) and anti-MICA antibodies or to p

106 tide- and lipid-based Ags presented by human leukocyte antigen (HLA) and CD1d, respectively.

107 ith high sensitivity in detecting anti-human leukocyte antigen (HLA) antibodies (Abs), have increased

108 impact of de novo donor-specific anti-human leukocyte antigen (HLA) antibodies (dnDSA) in the primar

109 splantation strong donor-specific anti-human leukocyte antigen (HLA) antibodies (DSA) are at higher r

110 De novo donor-specific human leukocyte antigen (HLA) antibodies (DSA) posttransplant

111 ular risk factors and circulating anti-human leukocyte antigen (HLA) antibodies.

112 y was also evaluated by measuring anti-human leukocyte antigen (HLA) antibodies.

113 idney recipients monitored for de novo human leukocyte antigen (HLA) antibody (Ab) occurrence to gain

114 he incidence of de novo donor-specific human leukocyte antigen (HLA) antibody (dnDSA) during the firs

115 Anti-human leukocyte antigen (HLA) antibody detection in solid-phas

116 itization a patient might have against human leukocyte antigen (HLA) antigens.

117 )) and confirm the previously reported human leukocyte antigen (HLA) associations on chromosome 6p21

118 fied by several key examples and their human leukocyte antigen (HLA) associations: abacavir and HLA-B

119 ecurrence was higher for patients with human leukocyte antigen (HLA) B49 (odds ratio, 16.9; 95% confi

120 Despite the progress in human leukocyte antigen (HLA) causal variant mapping, independ

121 The human leukocyte antigen (HLA) class I allele, HLA-C*06:02, is

122 complex (MHC) containing the classical human leukocyte antigen (HLA) Class I and Class II genes is am

123 The development of donor-specific human leukocyte antigen (HLA) class I antibodies after organ t

124 Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the reje

125 natural history of HIV infection, the human leukocyte antigen (HLA) class I genes exhibit the strong

126 Here we investigate the role of the human leukocyte antigen (HLA) class I genes in this biological

127 ts with chronic HBV infection, and the human leukocyte antigen (HLA) class I genotype (A and B loci)

128 dentification of peptides presented by human leukocyte antigen (HLA) class I is tremendously importan

129 Possession of the human leukocyte antigen (HLA) class I molecule B27 is strongly

130 ession down-regulates the nonclassical human leukocyte antigen (HLA) class I molecule HLA-G in human

131 on tumors and not on normal tissues by human leukocyte antigen (HLA) class I molecules are promising

132 or Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to peptid

133 r-specific antigens improves access to human leukocyte antigen (HLA) class I molecules for more effic

134 Human leukocyte antigen (HLA) class I molecules generally pres

135 ion of short viral peptide antigens by human leukocyte antigen (HLA) class I molecules on cell surfac

136 me generates the epitopes presented on human leukocyte antigen (HLA) class I molecules that elicit CD

137 several LRC products with polymorphic human leukocyte antigen (HLA) class I molecules.

138 wo broad strategies for recognition of human leukocyte antigen (HLA) class I molecules: (i) direct re

139 ct the link between hyperexpression of human leukocyte antigen (HLA) class I on the islet cells, we e

140 Humanized mice expressing Human Leukocyte Antigen (HLA) class I or II transgenes have be

141 Human leukocyte antigen (HLA) class I presents viral peptides

142 argeted capacity to selectively remove human leukocyte antigen (HLA) class I proteins from donor huma

143 Human leukocyte antigen (HLA) class I-associated polymorphisms

144 trometric observations of glycosylated human leukocyte antigen (HLA) class I-bound peptides.

145 ells, thus enabling their evasion from human leukocyte antigen (HLA) class I-restricted CD8(+) T-cell

146 e that allow it to escape detection by human leukocyte antigen (HLA) class I-restricted immune respon

147 ity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens i

148 rexin), is so strongly associated with human leukocyte antigen (HLA) class II HLA-DQA1( *)01:02-DQB1(

149 Here, we demonstrate the presence of human leukocyte antigen (HLA) class II-restricted CD8(+) T cel

150 unoglobulin-like receptors (KIRs) bind human leukocyte antigen (HLA) class-I (HLA-I) ligands and regu

151 ve emphasized ethnically heterogeneous human leukocyte antigen (HLA) classical allele associations to

152 The immunoregulatory human leukocyte antigen (HLA) complex has been linked to susce

153 (MHC) protein which is encoded by the human leukocyte antigen (HLA) complex.

154 ransplant antibodies directed at donor human leukocyte antigen (HLA) donor-specific antibodies (DSA)

155 9 Dutch children who were positive for human leukocyte antigen (HLA) DQ2/DQ8.

156 with ABMR associated with de novo anti-human leukocyte antigen (HLA) DSA.

157 mphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants.

158 Variation in the human leukocyte antigen (HLA) genes accounts for one-half of t

159 Human leukocyte antigen (HLA) genes confer substantial risk fo

160 ean descent by imputing class I and II human leukocyte antigen (HLA) genes from SNP genotype data.

161 erstanding of how variation within the human leukocyte antigen (HLA) genes influences risk of multipl

162 ymorphic genetic system in humans, the human leukocyte antigen (HLA) genes of the adaptive immune sys

163 NOTCH4, PLAUR, CSK, IRAK1, and several human leukocyte antigen (HLA) genes.

164 , 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [

165 ller immunoglobulin-like receptors and human leukocyte antigen (HLA) genotype with risk of CMV diseas

166 pport has been provided by analysis of human leukocyte antigen (HLA) haplotypes and genome-wide assoc

167 ght association of narcolepsy with the human leukocyte antigen (HLA) HLA-DQB1*06:02 allele, we first

168 this locus, we imputed alleles at classical leukocyte antigen (HLA) loci using HLA*IMP:02 with a ref

169 plantation consider information at the human leukocyte antigen (HLA) loci.

170 ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasi

171 The effect of donor-recipient human leukocyte antigen (HLA) matching on outcomes remains rel

172 donors and shorter waiting times over human leukocyte antigen (HLA) matching.

173 nce of AE increased with the number of human leukocyte antigen (HLA) mismatches (18%, 10%, and 5% in

174 Human leukocyte antigen (HLA) mismatches are known to influenc

175 Then, three decades ago, an unusual human leukocyte antigen (HLA) molecule was identified: HLA-G.

176 on the cell surface in the context of human leukocyte antigen (HLA) molecules have been targeted by

177 tors (KIRs) with their target ligands, human leukocyte antigen (HLA) molecules, is a critical compone

178 uding the antigen-presenting classical human leukocyte antigen (HLA) molecules.

179 th high-affinity binding of autologous human leukocyte antigen (HLA) molecules.

180 inding preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket.

181 se T cell repertoire and the extensive human leukocyte antigen (HLA) polymorphism across populations

182 host, and is linked to their allele of human leukocyte antigen (HLA) proteins, which present protein

183 additional susceptibility loci in the human leukocyte antigen (HLA) region are complicated by the st

184 ition to strong association within the human leukocyte antigen (HLA) region at 6p21 (Pmeta = 7.65 x 1

185 Additionally, the human leukocyte antigen (HLA) region was comprehensively studi

186 ino acid residues, and SNPs across the human leukocyte antigen (HLA) region were imputed and tested.

187 ancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele

188 ociation of 3 known JIA risk loci (the human leukocyte antigen (HLA) region, PTPN22 and PTPN2) and id

189 tability of IQ might lie hidden in the human leukocyte antigen (HLA) region, which plays a critical r

190 ne, the C11orf30/LRRC32 locus, and the human leukocyte antigen (HLA) region.

191 nd imputation was used to fine-map the human leukocyte antigen (HLA) region.

192 ssociation studies and SNPs within the human leukocyte antigen (HLA) region.

193 Patterns of human leukocyte antigen (HLA) restriction of immunodominant ep

194 In addition, human leukocyte antigen (HLA) serotypes were also imputed.

195 suitability for HSCT is determined by Human Leukocyte Antigen (HLA) similarity.

196 Human leukocyte antigen (HLA) supertypes are groups of functio

197 Genes of the human leukocyte antigen (HLA) system encode cell-surface prote

198 high sequence divergence harboring the human leukocyte antigen (HLA) system, we found that local real

199 purpose of this study was to identify human leukocyte antigen (HLA) type as risk and prognostic fact

200 Advancements in human leukocyte antigen (HLA) typing and supportive care have

201 Human leukocyte antigen (HLA) typing at the allelic level can

202 kflow Language (CWL) implementation of human leukocyte antigen (HLA) typing using Polysolver or HLAmi

203 Two human leukocyte antigen (HLA) variants, HLA-B*57 and -B*81, ar

204 Newborn screening for human leukocyte antigen (HLA) was done at St. Joseph's Hospita

205 in vitro model of ABMR due to class I human leukocyte antigen (HLA) with and without complement acti

206 e peptides associated with the class I human leukocyte antigen (HLA), of which 98 peptides were deriv

207 Aggregate morphologies also influence Human Leukocyte Antigen (HLA)--types recognized by the aggrega

208 the effect of allele-level matching at human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 in 1568 sin

209 r kidney allocation considers only the human leukocyte antigen (HLA)-A, HLA-B, and HLA-DR loci.

210 after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identif

211 e CD8(+) T cells in situ, in islets of human leukocyte antigen (HLA)-A2(+) donors and isolation and i

212 KK10 (KRWIILGLNK263-272) presented by human leukocyte antigen (HLA)-B *2705.

213 ted in one of the putative epitopes of human leukocyte antigen (HLA)-B*18-restricted cytotoxic T lymp

214 e reaction onset and identification of human leukocyte antigen (HLA)-B*57:01 as a susceptibility fact

215 Consecutive patients with AU who were human leukocyte antigen (HLA)-B27 positive or HLA-B27 negative

216 Identification of human leukocyte antigen (HLA)-bound peptides by liquid chromat

217 Human leukocyte antigen (HLA)-C*06:02 is identified as the all

218 udies suggest that the presence of the human leukocyte antigen (HLA)-Cw6 (C*06:02) allele may be a pr

219 Human leukocyte antigen (HLA)-DQ has emerged as the alloantibo

220 f age in 715 children positive for the human leukocyte antigen (HLA)-DQ2 and/or HLA-DQ8 from 5 Europe

221 Human leukocyte antigen (HLA)-DQ2.5 (DQA1*05/DQB1*02) is a cla

222 d T-cell epitopes presented in vivo by human leukocyte antigen (HLA)-DR molecules in patients' inflam

223 [OR], 7.07; P < .05), the presence of human leukocyte antigen (HLA)-DR7 (OR, 5.65; P < .05), and the

224 ine levels and number of copies of the human leukocyte antigen (HLA)-DRB1 (HLA-DRB1) shared epitope i

225 s have reported an association between human leukocyte antigen (HLA)-DRB1 and the risk of PD.

226 Specific alleles of the human leukocyte antigen (HLA)-DRB1 gene (HLA-DRB1) encode a "s

227 s (RA) is strongly associated with the human leukocyte antigen (HLA)-DRB1 locus that possesses the sh

228 estricted by the human MHC-Ib molecule human leukocyte antigen (HLA)-E and specific for an epitope fr

229 The banking of human leukocyte antigen (HLA)-homozygous-induced pluripotent s

230 Human leukocyte antigen (HLA)-I molecules can present long pep

231 or patients who do not have a suitable human leukocyte antigen (HLA)-matched family donor, unrelated

232 Human leukocyte antigen (HLA)-matched sibling donor (MSD) HSCT

233 We wanted to find out whether a male human leukocyte antigen (HLA)-matched unrelated donor (MUD, 8/

234 The role of B-cell subsets in human leukocyte antigen (HLA)-specific humoral responses in pa

235 A mouse model of human leukocyte antigen (HLA).A2 sensitization was used for st

236 inuclear antibodies (ANA), presence of human leukocyte antigen (HLA-)B27, age of onset of JIA, and se

237 gD, VP11/12, and VP13/14 proteins, in human leukocyte antigen (HLA-A*0201) transgenic rabbits infect

238 tributed to the genes encoding class I human leukocyte antigens (HLA) and the chemokine receptor CCR5

239 unoglobulin-like receptors (KIRs), and human leukocyte antigens (HLA) class I molecules.

240 We utilized mice transgenic for human leukocyte antigens (HLA) lacking the alpha/beta interfer

241 topes presented to CTLs by the class I human leukocyte antigens (HLA) of infected cells.

242 leles, genes or haplotypes) related to human leukocyte antigens (HLA), killer-cell immunoglobulin-lik

243 eveloped for other complex loci (e.g., human leukocyte antigen [HLA]) on the basis of SNP data provid

244 ed and mobilized within immunodominant human-leukocyte-antigen-(HLA)-A*11:01-restricted CD8(+) T cell

245 Understanding the binding between human leukocyte antigens (HLAs) and peptides is important to u

246 Human leukocyte antigens (HLAs) are a basic precondition to in

247 atibility complex (MHC), which encodes human leukocyte antigens (HLAs) in humans.

248 e-formed antibodies to population-wide human leukocyte antigens (HLAs) in patients being evaluated fo

249 tibodies recognizing denatured class I human leukocyte antigens (HLAs).

250 harboring genes encoding the class II human leukocyte antigens (HLAs): rs557011[T] (minor allele fre

251 om a deceased, living unrelated, or nonhuman leukocyte antigen identical living-related donor.

252 were simultaneously given marrow from a dog leukocyte antigen-identical donor.

253 ransplant options for patients without human leukocyte antigen-identical sibling or match unrelated d

254 m decreased lipid uptake and increased human leukocyte antigen II (HLA II) expression.

255 ransplanted with a positive crossmatch human leukocyte antigen-incompatible kidney between 2000 and 2

256 ransplanted with a positive crossmatch human leukocyte antigen-incompatible kidney between 2000 and 2

257 ed in this subset of closely monitored human leukocyte antigen-incompatible recipients throughout fol

258 iations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced dermat

259 methylation of the region encoding the human leukocyte antigen locus (HLA).

260 ve tissue disorder associated with the human leukocyte antigen locus.

261 , we present loss of heterozygosity in human leukocyte antigen (LOHHLA), a computational tool to dete

262 efined pre-transplant characteristics: human leukocyte antigen match (10/10 versus <10/10) and diseas

263 the recipient (younger donor or better human leukocyte antigen match), whereas delays beyond 3 months

264 ypothesis that tolerance to a VCA in our dog leukocyte antigen-matched canine model is not dependent

265 ereas others may not have a compatible human leukocyte antigen-matched donor.

266 ted information on 2985 patients given human leukocyte antigen-matched grafts to address this questio

267 t hematopoietic cell transplant from a human leukocyte antigen-matched sibling or from an unrelated d

268 cells (5.5-31.7 x 10(6) cells/kg) from human leukocyte antigen-matched siblings.

269 Eight dog leukocyte antigen-matched, minor antigen mismatched dogs

270 lar techniques have allowed for better human leukocyte antigen matching of unrelated adult donors.

271 ly BCAR+BL and CSWD (HR, 1.9; P<0.02), human leukocyte antigen mismatch (HR, 1.2; P<0.01), and age (H

272 (hazard ratio [HR], 4.72; P<0.002) and human leukocyte antigen mismatch (HR, 1.48; P<0.005) for early

273 Human leukocyte antigen mismatch number (hazards ratio, 1.35;

274 ent and donor characteristics, such as human leukocyte antigen mismatch, age, and use of antithymocyt

275 patible controls by age, gender, race, human leukocyte antigen mismatch, retransplantation, and trans

276 ative blood transfusions, reoperation, human leukocyte antigen mismatch, use of nonstandard immunosup

277 study, we extend those findings across a dog leukocyte antigen mismatched barrier.

278 o mixed lymphocyte co-cultures between human leukocyte antigen-mismatched peripheral blood lymphocyte

279 he two groups differed with respect to human leukocyte antigen mismatches (4.7 +/- 1.1 vs. 4.1 +/- 1.

280 in the adjusted models independent of human leukocyte antigen mismatches and initial immunosuppressi

281 s recipient, and increasing numbers of human leukocyte antigen mismatches were independent risk facto

282 basiliximab induction, sex, donor age, human leukocyte antigen mismatches, human leukocyte antigen an

283 ow that both alleles of genes encoding human leukocyte antigen molecules and genes encoding component

284 The HLA (human leukocyte antigen) molecules that present pathogen-deriv

285 peripheral blood mononuclear cells from dog leukocyte antigen-nonidentical dogs.

286 sed yeast-display libraries of peptide-human leukocyte antigen (pHLA) to screen for antigens of "orph

287 We tested the selectivity and efficacy of leukocyte antigen, PLAUR (plasminogen activator, urokina

288 ivated C3 localized at synapses within human leukocyte antigen-positive cell processes and lysosomes,

289 olymorphism rs41269979 in the class II human leukocyte antigen region was more frequent in the invasi

290 nalysis to dissect associations in the human leukocyte antigen region, which suggests important roles

291 extracellular diffusible ligands or require leukocyte antigen-related (Lar), a receptor protein tyro

292 d, the receptor protein tyrosine phosphatase leukocyte-antigen-related (LAR), abolished activity rhyt

293 One such phosphatase, leukocyte-antigen-related (LAR), abolishes activity rhyt

294 ank of transplantation, and absence of human leukocyte antigen sensitization.

295 ompatibility complex proteins to infer Swine Leukocyte Antigen (SLA) peptide binding preferences.

296 an knockout (KO) pig cells and class I swine leukocyte antigens (SLA).

297 ypes were detected among patients with human leukocyte antigen susceptibility alleles.

298 ween donor-specific antibodies against human leukocyte antigens type II (DSA II+) and transplant glom

299 D (n = 10) patients, alongside genomic human leukocyte antigen typing.

300 n tumor antigen NY-ESO-1 (ESO) and the human leukocyte antigen variant HLA-A*0201 (A2) as a model and